Cargando…
Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement
BACKGROUND: As vitamins and dietary supplements are obtainable without prescription, treating physicians often ignore their intake by patients with multiple sclerosis (MS) and may therefore miss potential adverse effects and interactions. OBJECTIVE: We aimed to assess the spectrum and intake frequen...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457677/ https://www.ncbi.nlm.nih.gov/pubmed/32922829 http://dx.doi.org/10.1177/2055217320936318 |
_version_ | 1783576043761696768 |
---|---|
author | Pape, Katrin Steffen, Falk Zipp, Frauke Bittner, Stefan |
author_facet | Pape, Katrin Steffen, Falk Zipp, Frauke Bittner, Stefan |
author_sort | Pape, Katrin |
collection | PubMed |
description | BACKGROUND: As vitamins and dietary supplements are obtainable without prescription, treating physicians often ignore their intake by patients with multiple sclerosis (MS) and may therefore miss potential adverse effects and interactions. OBJECTIVE: We aimed to assess the spectrum and intake frequency of supplementary medication in a cohort of MS patients and to analyse the effect of biotin intake on measurement of serum neurofilament light chain (sNfL), an emerging marker of disease activity. METHODS: MS patients visiting our neurology outpatient clinic completed a questionnaire on their past or present use of vitamins or dietary supplements. In addition, the impact of two different doses of biotin (10 and 300 mg/day) on sNfL was studied in healthy volunteers. RESULTS: Of 186 patients, 72.6% reported taking over-the-counter vitamins or dietary supplements currently or previously. Most frequently used was vitamin D (60.0%), followed by biotin. Female patients and patients with primary progressive MS tended to use supplements more frequently. Biotin intake did not interfere with sNfL measurement by single molecule array (Simoa). CONCLUSIONS: The use of vitamins and dietary supplements is frequent among patients with MS. Thus, treating physicians should be aware of the pitfalls of supplementary treatment and educate their patients accordingly. |
format | Online Article Text |
id | pubmed-7457677 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-74576772020-09-11 Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement Pape, Katrin Steffen, Falk Zipp, Frauke Bittner, Stefan Mult Scler J Exp Transl Clin Original Research Paper BACKGROUND: As vitamins and dietary supplements are obtainable without prescription, treating physicians often ignore their intake by patients with multiple sclerosis (MS) and may therefore miss potential adverse effects and interactions. OBJECTIVE: We aimed to assess the spectrum and intake frequency of supplementary medication in a cohort of MS patients and to analyse the effect of biotin intake on measurement of serum neurofilament light chain (sNfL), an emerging marker of disease activity. METHODS: MS patients visiting our neurology outpatient clinic completed a questionnaire on their past or present use of vitamins or dietary supplements. In addition, the impact of two different doses of biotin (10 and 300 mg/day) on sNfL was studied in healthy volunteers. RESULTS: Of 186 patients, 72.6% reported taking over-the-counter vitamins or dietary supplements currently or previously. Most frequently used was vitamin D (60.0%), followed by biotin. Female patients and patients with primary progressive MS tended to use supplements more frequently. Biotin intake did not interfere with sNfL measurement by single molecule array (Simoa). CONCLUSIONS: The use of vitamins and dietary supplements is frequent among patients with MS. Thus, treating physicians should be aware of the pitfalls of supplementary treatment and educate their patients accordingly. SAGE Publications 2020-08-27 /pmc/articles/PMC7457677/ /pubmed/32922829 http://dx.doi.org/10.1177/2055217320936318 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Paper Pape, Katrin Steffen, Falk Zipp, Frauke Bittner, Stefan Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement |
title | Supplementary medication in multiple sclerosis: Real-world experience
and potential interference with neurofilament light chain
measurement |
title_full | Supplementary medication in multiple sclerosis: Real-world experience
and potential interference with neurofilament light chain
measurement |
title_fullStr | Supplementary medication in multiple sclerosis: Real-world experience
and potential interference with neurofilament light chain
measurement |
title_full_unstemmed | Supplementary medication in multiple sclerosis: Real-world experience
and potential interference with neurofilament light chain
measurement |
title_short | Supplementary medication in multiple sclerosis: Real-world experience
and potential interference with neurofilament light chain
measurement |
title_sort | supplementary medication in multiple sclerosis: real-world experience
and potential interference with neurofilament light chain
measurement |
topic | Original Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457677/ https://www.ncbi.nlm.nih.gov/pubmed/32922829 http://dx.doi.org/10.1177/2055217320936318 |
work_keys_str_mv | AT papekatrin supplementarymedicationinmultiplesclerosisrealworldexperienceandpotentialinterferencewithneurofilamentlightchainmeasurement AT steffenfalk supplementarymedicationinmultiplesclerosisrealworldexperienceandpotentialinterferencewithneurofilamentlightchainmeasurement AT zippfrauke supplementarymedicationinmultiplesclerosisrealworldexperienceandpotentialinterferencewithneurofilamentlightchainmeasurement AT bittnerstefan supplementarymedicationinmultiplesclerosisrealworldexperienceandpotentialinterferencewithneurofilamentlightchainmeasurement |